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Pandemic peak 
SARS-CoV-2 infection 
and seroconversion rates 
in London frontline 
health-care workers
Nosocomial transmission of severe 
acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) is a major public health 
concern. Health -care workers (HCWs) 
are at high risk of developing COVID-19, 
and may themselves contribute to 
transmission.1
To evaluate these risks, we enrolled 
200 patient-facing HCWs between 
March 26 and April 8, 2020, in 
SARS-CoV-2 Acquisition in Frontline 
Healthcare Workers—Evaluation to 
inform Response (SAFER), a prospect-
ive cohort study in high-risk frontline 
HCWs in an acute National Health 
Service hospital trust in London. We 
collected nasopharyngeal swabs for 
RT-PCR twice per week, symptom 
data, and blood samples monthly 
for high-sensitivity serology assays 
(ELISA and flow cytometry for spike 
glycoprotein). Further methodology, 
study participant demographics, 
and the length of participation are 
described in the appendix.
87 (44%) of 200 HCWs had evidence 
of SARS-CoV-2 infec tion at any time-
point, detected either by serology or 
RT-PCR. Of the 200 HCWs, 181 gave a 
valid blood sample at two timepoints. 
On the basis of the composite ELISA 
and flow-cytometry serological 
results, 82 (45%) of 181 HCWs were 
seropositive after 1 month. 36 (20%) 
of 181 HCWs seroconverted during the 
study, and 46 (25%) of 181 HCWs were 
already seropositive at study entry. 
42 (21%) of 200 HCWs tested positive 
for SARS-CoV-2 by RT-PCR in at least 
one swab.
The median age of study partici pants 
was 34 years (IQR 29–44). There was a 
trend towards a higher infection rate 
in participants younger than 30 years 
(31 [55%] of 56 positive) compared to 
those older than 50 years (ten [33%] 
of 30 positive), with a reduction in 
log odds of positivity by 0·035 per 
year (p=0·0199). The mean duration 
of detection of SARS-CoV-2 RNA by 
RT-PCR was 12·9 days (first positive to 
last positive swab; 95% CI 9·4-17·3). 
The longest observed duration of 
SARS-CoV-2 detection was 29 days.
Asymptomatic carriage is an im-
por tant phenomenon associated 
with SARS-CoV-2 infection. Of the 
42 HCWs that ever tested positive 
for SARS-CoV-2 by RT-PCR, 20 (48%) 
reported symptoms within 7 days of 
the positive test that were consistent 
with Public Health England’s COVID-19 
case definition,2 and 16 (38%) did not 
report any symptoms in the same 
time frame. Six participants did not 
return symptom surveys within 7 days 
of their first positive PCR. The median 
time from first positive RT-PCR to first 
reported PHE case-definition symptom 
in 23 HCWs who reported symptoms 
at any timepoint during the study was 
4 days (appendix). No participants 
required hospital admission.
We compared the risk of SARS-CoV-2 
positive disease by RT-PCR detection 
in the 1 month of follow-up in those 
who tested negative by serology and 
RT-PCR at baseline (122 of 181 HCWs) 
with those who were positive by 
serology and negative by RT-PCR 
at baseline (33 of 181 HCWs). We 
excluded ten of the 122 HCWs who 
were negative by serology and RT-PCR 
at enrolment and seroconverted 
without having had a positive swab 
during follow-up (as these participants 
might represent seroconversions 
from infections acquired before the 
baseline sample, transient infection 
missed between swabs, or cross-
reactivity from exposure to seasonal 
coronaviruses). Of the remaining 
112 HCWs who were negative by 
RT-PCR and serology at enrolment, 
98 remained negative by RT-PCR, 
13 tested positive by RT-PCR and 
seroconverted, and one tested positive 
by RT-PCR but had not seroconverted 
by the second sampling timepoint (in 
a blood sample taken 17 days later).
This represents a 13% infection 
rate (ie, 14 of 112 HCWs) within the 
1 month of follow-up in those with 
no evidence of antibodies or viral 
shedding at enrolment. By contrast, 
of 33 HCWs who tested positive 
by serology but tested negative by 
RT-PCR at enrolment, 32 remained 
negative by RT-PCR through follow-
up, and one tested positive by RT-PCR 
on days 8 and 13 after enrolment.
Notwithstanding the short follow-
up period, these results suggest a 
protective effect, correlating with 
the presence of spike protein-specific 
antibodies, on subsequent infection 
within a 1-month period in a high-risk 
setting. Of the 26 HCWs who tested 
positive by RT-PCR at enrolment, 
13 already had antibodies at base-
line, indicating an anti-viral immune 
response, whereas the remaining 
13 HCWs seroconverted by the 1-month 
follow-up. All 46 HCWs testing 
positive for SARS-CoV-2 by serology at 
enrolment remained positive at follow-
up approximately 1 month later.
Of the 36 HCWs who seroconverted 
during the study, 19 had SARS-CoV-2 
RNA detected either at the time of 
enrolment or in the 7 days following 
enrolment. Of the remaining 17 HCWs 
who seroconverted, ten were staff in 
whom no SARS-CoV-2 was detected 
by RT-PCR during follow-up. Of the 
99 HCWs who were seronegative at both 
timepoints, only one tested positive by 
RT-PCR (on a single swab taken 17 days 
before the second serology test).
In this cohort of HCWs, most 
infections occurred between March 30 
and April 5, 2020, the week with the 
highest number of new cases in London 
(appendix). Personal protective equip-
ment (PPE) for all patient interac-
tions in England was introduced on 
April 1, 2020. Our results show that 
25% of HCWs were already seropositive 
at enrolment and that a further 20% of 
HCWs became seropositive within the 
first month of follow-up.
Our finding that 44% of HCWs 
show evidence of SARS-CoV-2 infec-
tion either by RT-PCR or serology 
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in a frontline setting is higher than 
reported by others in the UK and 
worldwide.3 Differences with Chinese3 
and Dutch4 data might be explained 
by the different study designs and the 
extent of implementation (or not) of 
both PPE and community lockdown 
measures. Evidence of infection in our 
central London HCWs was more than 
double that of the London population.5 
These data highlight the urgent 
need to implement policies to better 
protect HCWs and for regular asymp-
tomatic HCW surveillance in hospital 
settings that will protect both HCW 
staff and patients from nosocomial 
transmission through a potential 
SARS-CoV-2 second wave. Vaccines, 
if and when they become available, 
should initially be prioritised for HCWs.
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